MedTrace Logo

HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors

NCT06515314 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-12-02

No results posted yet for this study

Summary

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.

Conditions

  • Hepatic Cell Carcinoma

Interventions

BIOLOGICAL

AFP Specific T Cell Receptor T Cells

AFP Specific T Cell Receptor T Cells On day 1, the TCR-T cells will be administered intravenously. Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days

Sponsors & Collaborators

  • Shanghai Ruiliyuan Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaowu Huang, Doctor · Study Principal Investigator

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-17
Primary Completion
2026-08-10
Completion
2027-08-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06515314 on ClinicalTrials.gov